Applied BioMath LLC, the industry-leader in applying mechanistic modeling to drug research and development, announced a collaboration with Compass Therapeutics for the semi-mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling of a therapeutic targeting solid tumors. Semi-mechanistic PK/PD models will be developed for mouse, cynomolgus monkey, and human species and will help answer strategic questions such as the target coverage required for efficacy and dose regimen selection for the clinical study.

"We will use these models to help guide experiments and narrow down critical dosing and target coverage ranges to support an Investigational New Drug (IND)," said Michael Schmidt, vice president, antibody discovery and engineering at Compass Therapeutics LLC. "We've chosen to work with Applied BioMath due to their proven track record of helping companies accelerate their candidates into the clinic."

Applied BioMath is known for their robust fit-for-purpose modeling approach referred to as Model Aided Drug Invention (MADI). MADI leverages Applied BioMath's proprietary mathematical and high-performance computing software and algorithms to enable massive scale simulations in a very short timeframe. "MADI allows us to computationally explore numerous scenarios, including best case and worst case scenarios, for several molecules in a fraction of the time it would take to do the experiments in the lab," said Dr John Burke, PhD, co-founder, president, and CEO of Applied BioMath. "This is a big advantage in preclinical studies when companies are looking to quickly bring their candidate to the clinic."

Founded in 2013, Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development.